Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12162736 | 0.83 | ALDH1A1 (0.32) | — | |
| SCHEMBL21211628 | 0.82 | AR (0.32) | PTGS1PTGS2GABRA1GABRB2CA2 | |
| SCHEMBL20780894 | 0.81 | AR (0.32) | GABRA1GABRB2CA2 | |
| SCHEMBL11949591 | 0.80 | — | — | |
| SCHEMBL23772021 | 0.79 | CES2 (0.33) | PTGS1PTGS2CA2 | |
| SCHEMBL10197314 | 0.79 | ALOX5AP (0.32) | GABRA1GABRB2CA2 | |
| SCHEMBL4799568 | 0.76 | GABRA1 (0.37) | PTGS1PTGS2GABRA1GABRB2CA2 | |
| SCHEMBL20780624 | 0.74 | PTGS1 (0.32) | PTGS1PTGS2CA2 | |
| SCHEMBL17207218 | 0.74 | ALOX5AP (0.32) | GABRA1GABRB2CA2 | |
| SCHEMBL7136409 | 0.74 | CA2 (0.41) | PTGS1PTGS2GABRA1GABRB2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019280-A1 | SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-01-19 | — | — | US | disclosed |
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, CDV3, HMBS | PTGS1 3956/4885PTGS2 3292/4885GABRA1 2284/4885 |
| US-20230019280-A1 | SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, CDV3, HCCS | PTGS1 3563/4885PTGS2 2500/4885GABRA1 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.